Cargando…
Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
BACKGROUND: SHR7390 is a novel, selective MEK1/2 inhibitor. Here, we report results from two phase I trials conducted to evaluate the tolerability, safety and antitumor activity of SHR7390 monotherapy for advanced solid tumors and SHR7390 plus camrelizumab for treatment-refractory advanced or metast...
Autores principales: | Wei, Xiao-Li, Zhang, Yang, Zhao, Hong-Yun, Fang, Wen-Feng, Luo, Hui-Yan, Qiu, Miao-Zhen, He, Ming-Ming, Zou, Ben-Yan, Xie, Jie, Jin, Chun-Lei, Zhou, Xian-Feng, Wang, Feng, Wang, Feng-Hua, Li, Yu-Hong, Wang, Zhi-Qiang, Xu, Rui-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847543/ https://www.ncbi.nlm.nih.gov/pubmed/36398872 http://dx.doi.org/10.1093/oncolo/oyac225 |
Ejemplares similares
-
The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021) -
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
por: Morris, Van K, et al.
Publicado: (2023) -
Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023) -
Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023) -
Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)